Protagonist Therapeutics Inc - Asset Resilience Ratio
Protagonist Therapeutics Inc (PTGX) has an Asset Resilience Ratio of 65.90% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Protagonist Therapeutics Inc balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2024)
This chart shows how Protagonist Therapeutics Inc's Asset Resilience Ratio has changed over time. See net assets of Protagonist Therapeutics Inc for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Protagonist Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Protagonist Therapeutics Inc (PTGX) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $462.40 Million | 65.9% |
| Total Liquid Assets | $462.40 Million | 65.90% |
Asset Resilience Insights
- Very High Liquidity: Protagonist Therapeutics Inc maintains exceptional liquid asset reserves at 65.90% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Protagonist Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Protagonist Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Protagonist Therapeutics Inc (2014–2024)
The table below shows the annual Asset Resilience Ratio data for Protagonist Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 43.19% | $321.66 Million | $744.73 Million | -0.08pp |
| 2023-12-31 | 43.27% | $154.89 Million | $357.95 Million | -1.75pp |
| 2022-12-31 | 45.02% | $111.61 Million | $247.93 Million | -13.43pp |
| 2021-12-31 | 58.45% | $203.24 Million | $347.69 Million | +0.37pp |
| 2020-12-31 | 58.08% | $188.45 Million | $324.47 Million | -6.48pp |
| 2019-12-31 | 64.56% | $100.01 Million | $154.92 Million | +31.13pp |
| 2018-12-31 | 33.43% | $46.62 Million | $139.47 Million | +10.23pp |
| 2017-12-31 | 23.19% | $37.97 Million | $163.73 Million | -36.94pp |
| 2016-12-31 | 60.13% | $56.52 Million | $93.99 Million | +7.13pp |
| 2015-12-31 | 53.00% | $7.87 Million | $14.85 Million | +52.90pp |
| 2014-12-31 | 0.10% | $10.00K | $10.33 Million | -- |
About Protagonist Therapeutics Inc
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical tri… Read more